Published online before print April 17, 2006, doi: 10.1161/CIRCULATIONAHA.105.609974
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2006;113:1958-1965.)
© 2006 American Heart Association, Inc.
Epidemiology |
Prevalence and Determinants of Troponin T Elevation in the General Population
From the Donald W. Reynolds Cardiovascular Clinical Research Center and Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas (T.W.W., S.M.A., M.H.D., S.R.D., A.K., D.K.M., F.W., J.A.d.L.); and Donald W. Reynolds Cardiovascular Clinical Research Center, Brigham and Women’s Hospital, Boston, Mass (M.S.S., D.A.M.).
Correspondence to James A. de Lemos, MD, Division of Cardiology, University of Texas Southwestern Medical Center, 5909 Harry Hines Blvd, Room HA9.133, Dallas, TX 75390-9047. E-mail James.delemos{at}utsouthwestern.edu
Received November 7, 2005; de novo received December 21, 2005; revision received February 21, 2006; accepted February 23, 2006.
Background— The prevalence and determinants of cardiac troponin T (cTnT) elevation in the general population are unknown, and the significance of minimally increased cTnT remains controversial. Our objective was to determine the prevalence and determinants of cTnT elevation in a large, representative sample of the general population.
Methods and Results— cTnT was measured from stored plasma samples in 3557 subjects of the Dallas Heart Study, a population-based sample. cTnT elevation (
0.01 µg/L) was correlated with clinical variables and cardiac MRI findings. The sample weight-adjusted prevalence of cTnT elevation in the general population was 0.7%. In univariable analyses, cTnT elevation was associated with older age, black race, male sex, coronary artery calcium by electron beam CT, a composite marker of congestive heart failure (CHF), left ventricular hypertrophy (LVH), diabetes mellitus (DM), and chronic kidney disease (CKD) (P<0.001 for each). Subjects with minimally increased (0.01 to 0.029 µg/L) and increased (0.03 µg/L) cTnT had a similar prevalence of these characteristics. In multivariable logistic regression analysis, LVH, CHF, DM, and CKD were independently associated with cTnT elevation.
Conclusions— In the general population, cTnT elevation is rare in subjects without CHF, LVH, CKD, or DM, suggesting that the upper limit of normal for the immunoassay should be <0.01 µg/L. Even minimally increased cTnT may represent subclinical cardiac injury and have important clinical implications, a hypothesis that should be tested in longitudinal outcome studies.
CLINICAL PERSPECTIVE
This article has been cited by other articles:
 |
|
 |
|
  K. M. Eggers, L. Lind, H. Ahlstrom, T. Bjerner, C. Ebeling Barbier, A. Larsson, P. Venge, and B. Lindahl Prevalence and pathophysiological mechanisms of elevated cardiac troponin I levels in a population-based sample of elderly subjects Eur. Heart J., July 7, 2008; (2008) ehn327v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bankier, J. Barajas, A. Martinez-Rumayor, and J. L. Januzzi Association between C-reactive protein and generalized anxiety disorder in stable coronary heart disease patients Eur. Heart J., July 4, 2008; (2008) ehn326v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. D White Evolution of the definition of myocardial infarction: what are the implications of a new universal definition? Heart, June 1, 2008; 94(6): 679 - 684. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. de Lemos and D. M. Lloyd-Jones Multiple Biomarker Panels for Cardiovascular Risk Assessment N. Engl. J. Med., May 15, 2008; 358(20): 2172 - 2174. [Full Text] [PDF]
|
|
|
|
 |
|
 J. R Tate, W. Ferguson, R. Bais, K. Kostner, T. Marwick, and A. Carter The determination of the 99th centile level for troponin assays in an Australian reference population Ann Clin Biochem, May 1, 2008; 45(3): 275 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Eggers, B. Lagerqvist, P. Venge, L. Wallentin, and B. Lindahl Persistent Cardiac Troponin I Elevation in Stabilized Patients After an Episode of Acute Coronary Syndrome Predicts Long-Term Mortality Circulation, October 23, 2007; 116(17): 1907 - 1914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Latini, S. Masson, I. S. Anand, E. Missov, M. Carlson, T. Vago, L. Angelici, S. Barlera, G. Parrinello, A. P. Maggioni, et al. Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients With Stable Chronic Heart Failure Circulation, September 11, 2007; 116(11): 1242 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Yee-Moon Wang, C. Wai-Kei Lam, M. Wang, I. Hiu-Shuen Chan, W. B. Goggins, C.-M. Yu, S.-F. Lui, and J. E Sanderson Prognostic Value of Cardiac Troponin T Is Independent of Inflammation, Residual Renal Function, and Cardiac Hypertrophy and Dysfunction in Peritoneal Dialysis Patients Clin. Chem., May 1, 2007; 53(5): 882 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sakhuja, S. Green, E. M. Oestreicher, P. M. Sluss, E. Lee-Lewandrowski, K. B. Lewandrowski, and J. L. Januzzi Jr. Amino-Terminal Pro-Brain Natriuretic Peptide, Brain Natriuretic Peptide, and Troponin T for Prediction of Mortality in Acute Heart Failure Clin. Chem., March 1, 2007; 53(3): 412 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Jaffe Chasing Troponin: How Low Can You Go if You Can See the Rise? J. Am. Coll. Cardiol., November 7, 2006; 48(9): 1763 - 1764. [Full Text] [PDF]
|
|